NeuroSense Therapeutics L... (NRSNW)
0.27
-0.06 (-18.18%)
At close: Jan 28, 2025, 11:31 AM
Company Description
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for debilitating neurodegenerative diseases in Israel.
Its lead product candidate is PrimeC, a novel oral formulation for the treatment of amyotrophic lateral sclerosis.
The company's preclinical pipeline product candidates include StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease.
NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.
NeuroSense Therapeutics Ltd.
| Country | IL |
| IPO Date | n/a |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 18 |
| CEO | Alon Ben-Noon |
Contact Details
Address: Medinat ha-Yehudim Street 85 Herzliya, IL | |
| Website | https://www.neurosense-tx.com |
Stock Details
| Ticker Symbol | NRSNW |
| Exchange | NASDAQ |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | 0001875091 |
| CUSIP Number | M74240116 |
| ISIN Number | IL0011811630 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Alon Ben-Noon | Co-Founder, Chief Executive Officer & Director |
| Dr. Niva Russek-Blum Ph.D. | Chief Technology Officer |
| Or Eisenberg | Chief Financial Officer |
| Dr. Ferenc Tracik M.D. | Chief Medical Officer |
| Eidan Loushi | C.R.A. |
| Hagit Binder | Chief Operation Officer |
| Keren Pushett | Head of HR |
| Yael Barak | Vice President of Quality & Compliance |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 17, 2025 | 424B3 | Filing |
| Jan 06, 2025 | 6-K | Filing |
| Dec 26, 2024 | F-3 | Filing |
| Dec 23, 2024 | 6-K | Filing |
| Dec 18, 2024 | 6-K | Filing |
| Dec 17, 2024 | 6-K | Filing |
| Dec 12, 2024 | 424B3 | Filing |
| Dec 12, 2024 | D | Filing |
| Dec 11, 2024 | 6-K | Filing |
| Dec 09, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |